Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1618-1626

  Chou, Bin ^a,b   Hiromatsu, Kenji ^a   Okano, Shinji ^b   Ishii, Kazunari ^a   Duan, Xuefeng ^b   Sakai, Tohru ^c   Murata, Shigeo ^d   Tanaka, Keiji ^e   Himeno, Kunisuke ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 1; DNA VACCINE; GAMMA INTERFERON; GRANZYME B; IMMUNOPROTEASOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BLOOD VESSEL PARAMETERS; CANCER INHIBITION; CANCER SIZE; CANCER TISSUE; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENETIC TRANSFECTION; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOTOXICITY; MELANOMA; MICROVESSEL DENSITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; TRANSITIONAL CELL CARCINOMA; TUMOR VASCULARIZATION; UBIQUITINATION;

ANIMALS; AQUAPORIN 1; BLOTTING, WESTERN; CANCER VACCINES; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; UBIQUITIN; VACCINES, DNA;

EID: 84864812720     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101971     Document Type: Article

References (33)

1. Carter, E. P., B. P. Olveczky, M. A. Matthay, and A. S. Verkman. 1998. High microvascular endothelial water permeability in mouse lung measured by a pleural surface fluorescence method. Biophys. J. 74: 2121-2128. (Pubitemid 28157947)
2. Hasegawa, H., S. C. Lian, W. E. Finkbeiner, and A. S. Verkman. 1994. Extrarenal tissue distribution of CHIP28 water channels by in situ hybridization and antibody staining. Am. J. Physiol. 266: C893-C903.
3. Nielsen, S., B. L. Smith, E. I. Christensen, and P. Agre. 1993. Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc. Natl. Acad. Sci. USA 90: 7275-7279. (Pubitemid 23222432)
4. Endo, M., R. K. Jain, B.Witwer, and D. Brown. 1999.Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glioblastomas. Microvasc. Res. 58: 89-98. (Pubitemid 29419934)
5. Saadoun, S., M. C. Papadopoulos, D. C. Davies, B. A. Bell, and S. Krishna. 2002. Increased aquaporin 1 water channel expression in human brain tumours. Br. J. Cancer 87: 621-623.
6. Saadoun, S., M. C. Papadopoulos, M. Hara-Chikuma, and A. S. Verkman. 2005. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434: 786-792. (Pubitemid 44739524)
7. Frigeri, A., G. P. Nicchia, and M. Svelto. 2007. Aquaporins as targets for drug discovery. Curr. Pharm. Des. 13: 2421-2427. (Pubitemid 47317030)
8. Monzani, E., A. A. Shtil, and C. A. La Porta. 2007. The water channels, new druggable targets to combat cancer cell survival, invasiveness and metastasis. Curr. Drug Targets 8: 1132-1137. (Pubitemid 47578141)
9. Timmerman, J. M., and R. Levy. 1998. Melanoma vaccines: prim and proper presentation. Nat. Med. 4: 269-270. (Pubitemid 28144077)
10. Blazer, D. G., III, V. K. Sondak, and M. S. Sabel. 2007. Surgical therapy of cutaneous melanoma. Semin. Oncol. 34: 270-280.
11. Li, N., H. Qin, X. Li, C. Zhou, D. Wang, W. Ma, C. Lin, Y. Zhang, S. Wang, and S. Zhang. 2007. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J. Clin. Immunol. 27: 117-130. (Pubitemid 46224939)
12. Lin, X., C. Zhou, S. Wang, D. Wang, W. Ma, X. Liang, C. Lin, Z. Wang, J. Li, S. Guo, et al. 2006. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies. Int. J. Cancer 119: 1886-1896. (Pubitemid 44356847)
13. He, H., P. Wisner, G. Yang, H. M. Hu, D. Haley, W. Miller, A. O'Hara, W. G. Alvord, C. H. Clegg, B. A. Fox, et al. 2006. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 4: 24.
14. Shrayer, D. P., B. Cole, V. J. Hearing, S. F. Wolf, and H. J. Wanebo. 1999. Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleukin-12. Clin. Exp. Metastasis 17: 63-70. (Pubitemid 29284566)
15. Malmberg, K. J. 2004. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol. Immunother. 53: 879-892.
16. Pan, Z. K., L. M. Weiskirch, and Y. Paterson. 1999. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 59: 5264-5269. (Pubitemid 29503992)
17. Shibata, S., S. Okano, Y. Yonemitsu, M. Onimaru, S. Sata, H. Nagata-Takeshita, M. Inoue, T. Zhu, M. Hasegawa, Y. Moroi, et al. 2006. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J. Immunol. 177: 3564-3576. (Pubitemid 44359887)
18. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
19. Doherty, F. J., S. Dawson, and R. J. Mayer. 2002. The ubiquitin-proteasome pathway of intracellular proteolysis. Essays Biochem. 38: 51-63. (Pubitemid 36589194)
20. Pickart, C. M. 2001. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70: 503-533. (Pubitemid 32663902)
21. Tanaka, K., and M. Kasahara. 1998. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol. Rev. 163: 161-176. (Pubitemid 28327869)
22. Zhang, M., C. Obata, H. Hisaeda, K. Ishii, S. Murata, T. Chiba, K. Tanaka, Y. Li, M. Furue, B. Chou, et al. 2005. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte. Gene Ther. 12: 1049-1057. (Pubitemid 40946147)
23. Murata, S., H. Udono, N. Tanahashi, N. Hamada, K. Watanabe, K. Adachi, T. Yamano, K. Yui, N. Kobayashi, M. Kasahara, et al. 2001. Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J. 20: 5898-5907. (Pubitemid 33049265)
24. Ishii, K., H. Hisaeda, X. Duan, T. Imai, T. Sakai, H. J. Fehling, S. Murata, T. Chiba, K. Tanaka, S. Hamano, et al. 2006. The involvement of immunoproteasomes in induction of MHC class I-restricted immunity targeting Toxoplasma SAG1. Microbes Infect. 8: 1045-1053.
25. Kloetzel, P. M. 2001. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2: 179-187.
26. Rock, K. L., I. A. York, T. Saric, and A. L. Goldberg. 2002. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 80: 1-70. (Pubitemid 34625620)
27. Rosenberg, S. A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287. (Pubitemid 29165283)
28. Roberts, D. M., A. Nanda, M. J. Havenga, P. Abbink, D. M. Lynch, B. A. Ewald, J. Liu, A. R. Thorner, P. E. Swanson, D. A. Gorgone, et al. 2006. Hexonchimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
29. Zamir, G., E. Zeira, A. E. Gelman, A. Shaked, K. M. Olthoff, A. Eid, and E. Galun. 2007. Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression. Mol. Ther. 15: 772-781. (Pubitemid 46431998)
30. Fehling, H. J., W. Swat, C. Laplace, R. Kuhn, K. Rajewsky, U. Muller, and H. von Boehmer. 1994. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265: 1234-1237. (Pubitemid 24291982)
31. Li, Y., M. N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. Bohlen, and D. J. Hicklin. 2002. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195: 1575-1584. (Pubitemid 34666071)
32. Niethammer, A. G., R. Xiang, J. C. Becker, H. Wodrich, U. Pertl, G. Karsten, B. P. Eliceiri, and R. A. Reisfeld. 2002. A DNAvaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8: 1369-1375. (Pubitemid 36019421)
33. Reisfeld, R. A., A. G. Niethammer, Y. Luo, and R. Xiang. 2004. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol. Rev. 199: 181-190. (Pubitemid 38736771)